Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis

An observational study using real-world safety data among 462 patients with myelofibrosis found comparable ruxolitinib exposure-adjusted incidence rates (per 100 patients years) of adverse drug reactions among new users vs. prevalent ruxolitinib users (19.3 vs. 19.6), as well as serious adverse events (25.2 vs. 25.0). These and other findings from the study are consistent with safety data from the COMFORT/JUMP/EXPAND studies, further supporting the use of ruxolitinib for long-term treatment of myelofibrosis.